Skip to content

Biz News Today

Business News – Direct Source News

  • Home
  • Business News Videos
    • International/National News Videos
  • Directory
  • Links PRs
  • REITS
  • About
  • Contact
    • Sitemap

U.S. Food and Drug Administration Accepts for Priority Review Application for Opdivo® (nivolumab) as Adjuvant Therapy for Patients with Resected Esophageal or Gastroesophageal Junction Cancer

  • Home
  • 2021
  • January
  • 20
  • U.S. Food and Drug Administration Accepts for Priority Review Application for Opdivo® (nivolumab) as Adjuvant Therapy for Patients with Resected Esophageal or Gastroesophageal Junction Cancer

Original Source

On January 20, 2021

Post navigation

Previous PostMGM Resorts International Sponsors the Las Vegas Dr. Martin Luther King, Jr. Annual Virtual Parade
Next PostBristol Myers Squibb Announces Earnings Call Time Change; Fourth Quarter 2020 Earnings Call to Occur on February 4, 2021 at 10 a.m. (Eastern Time)

Related Post

August 7, 2022
  • Business News

S&P Daily Risk Control Covered Call Index Series Methodology

August 7, 2022
  • Business News

S&P Carbon Efficient Select Index Series Methodology

August 7, 2022
  • Business News

S&P Euro 75 Methodology

Copyright © All right reserved
Newslist Created By Rise Themes

Notice: ob_end_flush(): failed to send buffer of zlib output compression (0) in /home/biznews/public_html/wp-includes/functions.php on line 5219